Dr. Heather Snyder discusses the latest in disease-modifying treatments for Alzheimer's disease, including the newest medication, lecanemab, as well as promising therapeutics currently in the pipeline.
Heather Snyder, PhD, is the vice president of Medical and Scientific Relations at the Alzheimer’s Association. In this role, she oversees Association initiatives that accelerate innovative Alzheimer’s research and provide opportunities for the global dementia community to connect and collaborate. Dr. Snyder is responsible for the progress the Association has made in Alzheimer's and dementia research funding. She leads the Association’s International Research Grant Program, the vehicle through which the Association funds promising investigations that advance understanding of Alzheimer's and moves the field toward solutions for the global Alzheimer's crisis. As the world’s largest nonprofit funder of Alzheimer's research, the Association is currently investing over $250 million in 750 active best-of-field projects in 39 countries, spanning six continents. Dr. Snyder holds a PhD in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree from the University of Virginia.
Click here to access the recording of the event.